Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sakar Healthcare FCF Yield % Related Terms
Sakar Healthcare FCF Yield % Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sakar Healthcare (NSE:SAKAR) has a FCF Yield % of 1.06 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sakar Healthcare and its competitors. According to the industry distribution chart, Sakar Healthcare ranks #473 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 47%.
Is Sakar Healthcare's FCF Yield % too high?
Sakar Healthcare's current FCF Yield % is 1.06. The Drug Manufacturers industry median FCF Yield % is 0.69. Sakar Healthcare's value of 1.06 is 53.6% above this industry median. Based on the distribution chart, Sakar Healthcare ranks #473 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #473 out of 1006 companies for FCF Yield %. This puts Sakar Healthcare in the upper half of its industry. The industry median FCF Yield % is 0.69. Sakar Healthcare's value of 1.06 is 53.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakar Healthcare's current FCF Yield % of 1.06 is 53.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current FCF Yield % is 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current FCF Yield % is 1.06 and 53.6% above the Drug Manufacturers industry median of 0.69. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current FCF Yield % is 1.06 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
FCF Yield %: 1.06
GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
Industry Position: 53.6% above the Drug Manufacturers median (#473 of 1006)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
